Indian Pharma CRDMOs Projected for 13-15% Revenue Growth, Strengthening Credit Profiles

Indian contract research, development, and manufacturing organizations (CRDMOs) are positioned to maintain strong credit profiles due to robust cash flows, according to Crisil Ratings. This financial strength will allow them to continue investing in capital expenditures (capex) with minimal dependence on debt. The analysis indicates revenue growth for pharma CRDMOs is projected to be between 13 and 15 percent. This growth is supported by the ongoing trend of supply-chain derisking. Crisil Ratings reports that the resultant cash flows will provide Indian CRDMOs with the financial flexibility to fund capital expenditure plans, reducing the need for debt financing and contributing to the maintenance of healthy credit ratings.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Related posts:

Neurons Linked to Risk and Reward Decisions Identified New Study Reveals Brain Activity in Small Groups Can Predict Mass Decision-Making Brain Tumor Surgery: Real-Time DNA Analysis Paves the Way for Personalized Treatment Training in Future Thinking Proven to Reduce Impulsivity, Enhance Decision-Making

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後